LifeMD (NASDAQ:LFMD) Price Target Cut to $8.00 by Analysts at B. Riley Financial

LifeMD (NASDAQ:LFMD) had its price objective reduced by analysts at B. Riley Financial from $10.00 to $8.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s target price suggests a potential upside of 142.72% from the company’s current price.

LFMD has been the subject of a number of other reports. BTIG Research lowered their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a report on Tuesday, May 26th. Zacks Research downgraded LifeMD from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Mizuho set a $7.00 price target on LifeMD in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.57.

LifeMD Trading Down 10.4%

Shares of NASDAQ:LFMD traded down $0.38 during trading on Thursday, hitting $3.30. 1,854,133 shares of the stock were exchanged, compared to its average volume of 1,070,411. The company has a fifty day moving average price of $4.43 and a two-hundred day moving average price of $3.98. The company has a market cap of $159.40 million, a PE ratio of 65.93 and a beta of 2.02. LifeMD has a 12-month low of $2.56 and a 12-month high of $7.32.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. Equities research analysts anticipate that LifeMD will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after buying an additional 2,235 shares during the period. Tower Research Capital LLC TRC boosted its stake in LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. SG Americas Securities LLC grew its position in LifeMD by 13.8% during the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares in the last quarter. Invesco Ltd. raised its stake in LifeMD by 18.8% during the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after purchasing an additional 3,870 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after purchasing an additional 4,281 shares in the last quarter. Institutional investors own 35.52% of the company’s stock.

Key Headlines Impacting LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: LifeMD reported second-quarter revenue of $47.3 million, within its guidance range, while active subscribers grew 20% year over year to approximately 356,000. Weight Management subscribers reached about 108,000. LifeMD Reports Second Quarter 2026 Results
• Positive Sentiment: Gross margin expanded to approximately 89% from 86% a year earlier, helped by lower shipping and fulfillment costs and the scaling of LifeMD’s in-house pharmacy. The adjusted EBITDA loss improved 21% sequentially to roughly $3.5 million.
• Positive Sentiment: LifeMD said approximately 95% of new weight-management patients now start branded GLP-1 therapies, and expects to return to positive adjusted EBITDA in the second half of 2026. The company ended the quarter with $25.1 million in cash, no debt and $30 million available under its revolving credit facility.
• Neutral Sentiment: The transition away from compounded GLP-1 medications is reducing upfront revenue but is intended to create longer-duration memberships and more predictable recurring revenue. Management also highlighted an XYOSTED® telehealth collaboration and expanding Women’s Health, pharmacy, insurance and enterprise opportunities. LifeMD Reports Second Quarter 2026 Results, Reaches Branded GLP-1 Transition Milestone and Raises Full-Year Guidance
• Negative Sentiment: GAAP loss attributable to common stockholders widened to $7.9 million, or $0.16 per share, from $3.8 million, or $0.09 per share, in the prior-year quarter. Revenue also fell from $49.0 million, and was below the approximately $49.2 million analyst consensus cited in the reports.
• Negative Sentiment: Management cut full-year 2026 revenue guidance to $205.5 million-$212.5 million from $220 million-$230 million. Adjusted EBITDA guidance was reduced to a loss of $6 million through breakeven from $12 million-$17 million, while third-quarter revenue guidance of $48 million-$51 million is below consensus expectations. LifeMD Reports Q2 Loss, Lags Revenue Estimates

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.